AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on ...

U.S. tariff revenues hit a record $100 billion, but most new tariffs haven't taken effect yet, signaling more economic ...

The drugmaker has invested $10 billion in Wake and Durham counties over the past 30 years. Biogen says that figure will ...

The European Union still wants a trade pact with the US, but the bloc said to be readying its counterattack as President ...

President Donald Trump has threatened tariffs on drugs coming from overseas, but it might take more than that to reroute the ...

Targeting European allies won't fix any of our problems with China, or improve health care, writes Josh Steuterman.

Biogen will invest an additional $2 billion in its existing manufacturing in North Carolina, the drugmaker said on Monday, as ...

President Trump’s threat to impose 30% tariffs on the European Union disrupted negotiations. From cars to wine, these are the ...

By K Raveendran The Trump administration’s twin-pronged approach to force India into granting greater trade concessions marks ...

The deadline on US pharmaceutical tariffs has been dramatically brought forward, in the latest escalation of Donald Trump's ...

President Donald Trump’s tariff strategy is less about trade and more about geopolitical blackmail. By refusing to be rushed ...